• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

European Hematology Association

June 12 - 15, 2025

  1. Acalabrutinib
  2. AZD0120
  3. Surovatamig (AZD0486)

pdf

Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial

pdf

Venetoclax-acalabrutinib for CLL patients relapsing after venetoclax-antiCD20 treatment: Highly effective and low toxicity. Interim analysis of HOVON 159/REVEAL phase 2 trial

pdf

Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the phase 3 ECHO trial

pdf

Measurable residual disease kinetics with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia: Data from the phase 3 AMPLIFY trial

pdf

Analysis of COVID-19 infections with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia in the phase 3 AMPLIFY trial

pdf

Real-world treatment patterns and outcomes among patients with treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

pdf

Real-world treatment patterns and outcomes among patients with high-risk, treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

pdf

Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

pdf 

Autologous B cell maturation antigen (BCMA) and CD19 dual targeting FasTCAR-T cells (GC012F/AZD0120) as first-line therapy for elderly patients with newly diagnosed multiple myeloma patients

pdf 

Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: Early results from the phase 1/2 SYRUS study

pdf 

Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No